StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Stock analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th.

Aptose Biosciences Stock Performance

APTO stock opened at $0.18 on Friday. The firm has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $0.57. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.91. The company has a market capitalization of $3.26 million, a P/E ratio of -0.06 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.